Juvenile Arthritis News

Novartis announced the FDA has granted breakthrough therapy designations for canakinumab to treat three rare periodic fever syndromes — tumor necrosis factor receptor-associated periodic syndrome, hyperimmunoglobulin D syndrome/mevalonate kinase deficiency and familial Mediterranean fever — for patients with an inadequate response to colchicine, according to a company press release.

The most highly accessed articles about pain management in rheumatology included a survey about NSAIDs. Other articles of interest highlighted fatigue associated with pain and issues related to fibromyalgia.

A new industry body, the British Biosimilars Association, has been launched to promote the use of biosimilar drug treatments in the United Kingdom, according to a press release.

Modernizing medicine, Inc. announced the launch of its modmed Electronic Medical Assistant for pain medicine, a specialty-specific, cloud-based electronic health record system with tap and touch features providing access to an anatomic atlas.

The most highly accessed articles about biosimilars on Healio.com/Rheumatology have largely focused on the reaction to the FDA approval of the first biosimilar to infliximab in the United States.

Following FDA approval of Celltrion’s biosimilar to Janssen’s infliximab, Prime Therapeutics LLC issued a statement noting it remains “cautiously optimistic” about the future of biosimilar agents in the United States and urged regulators to finalize decisions on their use.

A sustainable balance between the emotional, social and vocational aspects of treatment with young patients between the ages of 16 and 25 years with arthritis

NEW YORK CITY — Stephen I. Katz, MD, PhD, director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the NIH, presented the keynote speech at the Interdisciplinary Autoimmune Summit and urged rheumatologists, dermatologists, gastroenterologists and other health care professionals who treat patients with autoimmune diseases to work together. He also discussed the future work of NIH research into autoimmune diseases from a multidisciplinary approach.

Patients with enthesitis-related arthritis and a high BMI were less likely to achieve inactive disease at 1 year, according to a recently published report.

HOLLYWOOD, Fla. —Gregg J. Silverman, MD, associate director of the Division of Rheumatology and professor of medicine and pathology at the New York University School of Medicine spoke with Healio.com/Rheumatology about the immune system in cancer therapy and the pathogenesis of autoimmune diseases..